Helius Cash Conversion Cycle vs Begin Period Cash Flow Analysis

HSDT Stock

USD 0.54 0.05 8.47%

Helius Medical financial indicator trend analysis is much more than just examining Helius Medical Techn latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Helius Medical Techn is a good investment. Please check the relationship between Helius Medical Cash Conversion Cycle and its Begin Period Cash Flow accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helius Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Cash Conversion Cycle vs Begin Period Cash Flow

Cash Conversion Cycle vs Begin Period Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Helius Medical Techn Cash Conversion Cycle account and Begin Period Cash Flow. At this time, the significance of the direction appears to have no relationship.

The correlation between Helius Medical's Cash Conversion Cycle and Begin Period Cash Flow is 0.02. Overlapping area represents the amount of variation of Cash Conversion Cycle that can explain the historical movement of Begin Period Cash Flow in the same time period over historical financial statements of Helius Medical Technologies, assuming nothing else is changed. The correlation between historical values of Helius Medical's Cash Conversion Cycle and Begin Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Conversion Cycle of Helius Medical Technologies are associated (or correlated) with its Begin Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Begin Period Cash Flow has no effect on the direction of Cash Conversion Cycle i.e., Helius Medical's Cash Conversion Cycle and Begin Period Cash Flow go up and down completely randomly.

Correlation Coefficient

0.02

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Cash Conversion Cycle

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Most indicators from Helius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Helius Medical Techn current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Helius Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

At this time, Helius Medical's Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.02 in 2025, whereas Selling General Administrative is likely to drop slightly above 9.6 M in 2025.

Helius Medical fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Current Liab	Other Liab	Long Term Debt	Net Receivables	Retained Earnings Total Equity	Short Term Investments	Non Current Liabilities Total	Capital Surpluse	Other Stockholder Equity
Common Stock Shares Outstanding		-0.19	-0.13	-0.16	-0.19	0.17	0.31	0.22	-0.18	-0.19	0.25	0.25	-0.14	-0.24	-0.17	0.16	0.25	-0.07	-0.09	-0.02	0.02	0.37	0.11	-0.11	-0.33	-0.32
Total Assets	-0.19		0.61	0.74	0.69	-0.97	-0.67	0.33	0.99	0.99	-0.19	0.6	0.77	0.71	0.99	0.52	-0.19	0.59	0.14	0.47	0.39	-0.7	-0.11	0.33	0.68	0.63
Total Current Liabilities	-0.13	0.61		0.01	-0.07	-0.68	-0.09	0.81	0.66	0.66	0.48	-0.02	0.89	0.36	0.63	0.71	0.48	0.98	-0.35	0.18	0.32	-0.2	0.16	0.14	0.02	-0.04
Total Stockholder Equity	-0.16	0.74	0.01		0.87	-0.69	-0.61	-0.23	0.7	0.69	-0.7	0.59	0.15	0.45	0.71	0.17	-0.7	0.03	0.14	0.25	0.04	-0.61	-0.05	0.0	0.73	0.68
Net Tangible Assets	-0.19	0.69	-0.07	0.87		-0.59	-0.79	-0.35	0.64	0.64	-0.71	0.69	0.19	0.61	0.67	0.05	-0.71	-0.06	0.55	0.54	0.28	-0.73	-0.43	0.18	0.89	0.89
Net Debt	0.17	-0.97	-0.68	-0.69	-0.59		0.52	-0.36	-0.99	-0.99	0.14	-0.51	-0.79	-0.57	-0.98	-0.62	0.14	-0.69	-0.04	-0.33	-0.26	0.56	-0.03	-0.34	-0.52	-0.48
Retained Earnings	0.31	-0.67	-0.09	-0.61	-0.79	0.52		0.03	-0.57	-0.57	0.29	-0.76	-0.41	-0.91	-0.64	0.16	0.29	0.01	-0.57	-0.74	-0.68	0.97	0.38	-0.39	-0.95	-0.96
Accounts Payable	0.22	0.33	0.81	-0.23	-0.35	-0.36	0.03		0.34	0.34	0.8	0.04	0.71	0.31	0.33	0.53	0.8	0.73	-0.46	0.18	0.42	-0.07	0.24	0.04	-0.17	-0.22
Cash	-0.18	0.99	0.66	0.7	0.64	-0.99	-0.57	0.34		1.0	-0.16	0.53	0.79	0.62	0.99	0.59	-0.16	0.66	0.11	0.39	0.3	-0.6	-0.08	0.35	0.58	0.54
Cash And Short Term Investments	-0.19	0.99	0.66	0.69	0.64	-0.99	-0.57	0.34	1.0		-0.16	0.53	0.79	0.62	0.99	0.6	-0.16	0.66	0.11	0.39	0.3	-0.6	-0.08	0.35	0.58	0.54
Common Stock Total Equity	0.25	-0.19	0.48	-0.7	-0.71	0.14	0.29	0.8	-0.16	-0.16		-0.18	0.38	0.01	-0.16	0.17	1.0	0.39	-0.33	0.02	0.27	0.24	0.18	0.12	-0.5	-0.48
Other Current Assets	0.25	0.6	-0.02	0.59	0.69	-0.51	-0.76	0.04	0.53	0.53	-0.18		0.33	0.68	0.6	0.04	-0.18	-0.07	0.53	0.69	0.53	-0.71	-0.23	0.47	0.71	0.73
Total Liab	-0.14	0.77	0.89	0.15	0.19	-0.79	-0.41	0.71	0.79	0.79	0.38	0.33		0.63	0.8	0.61	0.38	0.84	0.07	0.46	0.54	-0.46	-0.11	0.48	0.32	0.29
Short Long Term Debt	-0.24	0.71	0.36	0.45	0.61	-0.57	-0.91	0.31	0.62	0.62	0.01	0.68	0.63		0.68	0.04	0.01	0.23	0.4	0.8	0.78	-0.91	-0.42	0.32	0.85	0.84
Total Current Assets	-0.17	0.99	0.63	0.71	0.67	-0.98	-0.64	0.33	0.99	0.99	-0.16	0.6	0.8	0.68		0.55	-0.16	0.62	0.17	0.46	0.38	-0.66	-0.11	0.38	0.64	0.6
Short Term Debt	0.16	0.52	0.71	0.17	0.05	-0.62	0.16	0.53	0.59	0.6	0.17	0.04	0.61	0.04	0.55		0.17	0.81	-0.33	-0.03	-0.11	0.09	0.19	-0.04	-0.11	-0.17
Common Stock	0.25	-0.19	0.48	-0.7	-0.71	0.14	0.29	0.8	-0.16	-0.16	1.0	-0.18	0.38	0.01	-0.16	0.17		0.39	-0.33	0.02	0.27	0.24	0.18	0.12	-0.5	-0.48
Other Current Liab	-0.07	0.59	0.98	0.03	-0.06	-0.69	0.01	0.73	0.66	0.66	0.39	-0.07	0.84	0.23	0.62	0.81	0.39		-0.36	0.09	0.18	-0.08	0.18	0.11	-0.05	-0.11
Other Liab	-0.09	0.14	-0.35	0.14	0.55	-0.04	-0.57	-0.46	0.11	0.11	-0.33	0.53	0.07	0.4	0.17	-0.33	-0.33	-0.36		0.55	0.42	-0.4	-0.68	0.66	0.54	0.66
Long Term Debt	-0.02	0.47	0.18	0.25	0.54	-0.33	-0.74	0.18	0.39	0.39	0.02	0.69	0.46	0.8	0.46	-0.03	0.02	0.09	0.55		0.8	-0.72	-0.59	0.35	0.71	0.74
Net Receivables	0.02	0.39	0.32	0.04	0.28	-0.26	-0.68	0.42	0.3	0.3	0.27	0.53	0.54	0.78	0.38	-0.11	0.27	0.18	0.42	0.8		-0.64	-0.3	0.41	0.55	0.57
Retained Earnings Total Equity	0.37	-0.7	-0.2	-0.61	-0.73	0.56	0.97	-0.07	-0.6	-0.6	0.24	-0.71	-0.46	-0.91	-0.66	0.09	0.24	-0.08	-0.4	-0.72	-0.64		0.32	-0.28	-0.94	-0.91
Short Term Investments	0.11	-0.11	0.16	-0.05	-0.43	-0.03	0.38	0.24	-0.08	-0.08	0.18	-0.23	-0.11	-0.42	-0.11	0.19	0.18	0.18	-0.68	-0.59	-0.3	0.32		-0.17	-0.48	-0.54
Non Current Liabilities Total	-0.11	0.33	0.14	0.0	0.18	-0.34	-0.39	0.04	0.35	0.35	0.12	0.47	0.48	0.32	0.38	-0.04	0.12	0.11	0.66	0.35	0.41	-0.28	-0.17		0.23	0.32
Capital Surpluse	-0.33	0.68	0.02	0.73	0.89	-0.52	-0.95	-0.17	0.58	0.58	-0.5	0.71	0.32	0.85	0.64	-0.11	-0.5	-0.05	0.54	0.71	0.55	-0.94	-0.48	0.23		0.99
Other Stockholder Equity	-0.32	0.63	-0.04	0.68	0.89	-0.48	-0.96	-0.22	0.54	0.54	-0.48	0.73	0.29	0.84	0.6	-0.17	-0.48	-0.11	0.66	0.74	0.57	-0.91	-0.54	0.32	0.99

Click cells to compare fundamentals

Helius Medical Account Relationship Matchups

Helius Medical fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Common Stock Shares Outstanding	24.0K	49.1K	269.9K	607.9K	547.1K	519.7K
Total Assets	6.5M	14.1M	17.3M	7.7M	8.8M	9.9M
Total Current Liabilities	2.4M	2.7M	2.0M	1.9M	1.7M	1.6M
Total Stockholder Equity	3.9M	11.3M	8.2M	2.4M	2.7M	2.9M
Net Tangible Assets	4.0M	3.9M	10.2M	8.0M	9.2M	9.7M
Net Debt	(3.2M)	(11.0M)	(14.4M)	(5.1M)	(4.6M)	(4.8M)
Retained Earnings	(118.9M)	(137.0M)	(151.1M)	(160.0M)	(144.0M)	(136.8M)
Accounts Payable	747K	1.1M	627K	531K	477.9K	454.0K
Cash	3.3M	11.0M	14.5M	5.2M	6.0M	7.6M
Cash And Short Term Investments	3.3M	11.0M	14.5M	5.2M	6.0M	7.7M
Liabilities And Stockholders Equity	6.5M	14.1M	17.3M	7.7M	8.8M	9.9M
Other Current Assets	735K	862K	1.2M	829K	953.4K	757.9K
Total Liab	2.7M	2.8M	9.1M	5.3M	6.1M	7.1M
Total Current Assets	4.7M	12.6M	16.7M	7.4M	8.6M	9.1M
Short Term Debt	118K	6K	108K	45K	40.5K	38.5K
Common Stock	31K	1K	4K	28K	900.0	855.0
Other Current Liab	1.3M	1.2M	1.2M	1.1M	982.8K	933.7K
Net Receivables	230K	251K	343K	637K	732.6K	401.2K
Non Current Liabilities Total	252K	193K	7.1M	3.5M	4.0M	2.6M
Other Stockholder Equity	123.9M	149.4M	159.6M	163.0M	187.4M	196.8M
Accumulated Other Comprehensive Income	(1.1M)	(1.1M)	(388K)	(673K)	(774.0K)	(812.6K)
Non Current Assets Total	1.9M	1.5M	590K	254K	292.1K	277.5K
Non Currrent Assets Other	(1.9M)	(1.5M)	(590K)	140K	126K	132.3K
Property Plant And Equipment Net	576K	412K	450K	230K	207K	196.7K
Current Deferred Revenue	281K	148K	27K	43K	38.7K	36.8K
Net Invested Capital	3.9M	11.3M	8.2M	2.4M	2.7M	5.3M
Property Plant And Equipment Gross	576K	412K	450K	589K	677.4K	631.4K
Net Working Capital	2.3M	9.9M	14.7M	5.6M	6.4M	5.8M
Property Plant Equipment	1.3M	486K	412K	450K	517.5K	612.2K
Inventory	389K	476K	589K	790K	908.5K	592.9K
Capital Stock	31K	1K	4K	28K	900.0	855.0
Short Long Term Debt Total	91K	3K	110K	57K	51.3K	48.7K
Capital Lease Obligations	91K	3K	110K	57K	51.3K	48.7K
Intangible Assets	527K	333K	140K	24K	21.6K	20.5K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Helius Stock Analysis

When running Helius Medical's price analysis, check to measure Helius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helius Medical is operating at the current time. Most of Helius Medical's value examination focuses on studying past and present price action to predict the probability of Helius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helius Medical's price. Additionally, you may evaluate how the addition of Helius Medical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC